JP4276840B2 - 神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 - Google Patents
神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 Download PDFInfo
- Publication number
- JP4276840B2 JP4276840B2 JP2002567292A JP2002567292A JP4276840B2 JP 4276840 B2 JP4276840 B2 JP 4276840B2 JP 2002567292 A JP2002567292 A JP 2002567292A JP 2002567292 A JP2002567292 A JP 2002567292A JP 4276840 B2 JP4276840 B2 JP 4276840B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- formula
- disease
- group
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims description 53
- 238000011282 treatment Methods 0.000 title claims description 16
- 230000002265 prevention Effects 0.000 title claims description 9
- 150000004657 carbamic acid derivatives Chemical class 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 32
- 208000014674 injury Diseases 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 208000027418 Wounds and injury Diseases 0.000 claims description 26
- 230000006378 damage Effects 0.000 claims description 25
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 24
- 230000001684 chronic effect Effects 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 230000001154 acute effect Effects 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 206010008118 cerebral infarction Diseases 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 12
- 208000028867 ischemia Diseases 0.000 claims description 12
- 230000007850 degeneration Effects 0.000 claims description 11
- 201000001119 neuropathy Diseases 0.000 claims description 11
- 230000007823 neuropathy Effects 0.000 claims description 11
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 11
- 230000016273 neuron death Effects 0.000 claims description 10
- 208000029028 brain injury Diseases 0.000 claims description 9
- 230000002124 endocrine Effects 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 230000001537 neural effect Effects 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- 208000034693 Laceration Diseases 0.000 claims description 7
- 206010033799 Paralysis Diseases 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 230000009692 acute damage Effects 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 230000001146 hypoxic effect Effects 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 208000034656 Contusions Diseases 0.000 claims description 6
- 201000004810 Vascular dementia Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 230000006835 compression Effects 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 230000009519 contusion Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 208000005264 motor neuron disease Diseases 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 208000000044 Amnesia Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 230000006984 memory degeneration Effects 0.000 claims description 5
- 208000023060 memory loss Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000021090 palsy Diseases 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 4
- 230000036461 convulsion Effects 0.000 claims description 4
- 230000001054 cortical effect Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 238000007917 intracranial administration Methods 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 102000007371 Ataxin-3 Human genes 0.000 claims description 3
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 208000001730 Familial dysautonomia Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 3
- 208000027747 Kennedy disease Diseases 0.000 claims description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 3
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 240000007817 Olea europaea Species 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 206010036590 Premature baby Diseases 0.000 claims description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 208000005587 Refsum Disease Diseases 0.000 claims description 3
- 201000001638 Riley-Day syndrome Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 3
- 208000032859 Synucleinopathies Diseases 0.000 claims description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 3
- 206010063661 Vascular encephalopathy Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000030597 adult Refsum disease Diseases 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 208000025434 cerebellar degeneration Diseases 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 230000003073 embolic effect Effects 0.000 claims description 3
- 230000008175 fetal development Effects 0.000 claims description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 208000037906 ischaemic injury Diseases 0.000 claims description 3
- 206010023497 kuru Diseases 0.000 claims description 3
- 201000010901 lateral sclerosis Diseases 0.000 claims description 3
- 231100000518 lethal Toxicity 0.000 claims description 3
- 230000001665 lethal effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000011458 pharmacological treatment Methods 0.000 claims description 3
- 208000001282 primary progressive aphasia Diseases 0.000 claims description 3
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 230000001732 thrombotic effect Effects 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 210000003792 cranial nerve Anatomy 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 206010050389 Cerebral ataxia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010033885 Paraparesis Diseases 0.000 claims 1
- 208000002548 Spastic Paraparesis Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 10
- -1 alkyl carbamate Chemical compound 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical class NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 0 *N(*)C(OCC(c1ccccc1)O)=O Chemical compound *N(*)C(OCC(c1ccccc1)O)=O 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010073681 Epidural haemorrhage Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010033892 Paraplegia Diseases 0.000 description 2
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000002667 Subdural Hematoma Diseases 0.000 description 2
- 206010042364 Subdural haemorrhage Diseases 0.000 description 2
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 229920002310 Welan gum Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000003388 posterior cerebral artery Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168201P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/005541 WO2002067925A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| US10/081,764 US20020165273A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523555A JP2004523555A (ja) | 2004-08-05 |
| JP2004523555A5 JP2004523555A5 (enExample) | 2005-12-22 |
| JP4276840B2 true JP4276840B2 (ja) | 2009-06-10 |
Family
ID=26765943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567292A Expired - Fee Related JP4276840B2 (ja) | 2001-02-27 | 2002-02-21 | 神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20020165273A1 (enExample) |
| EP (1) | EP1383489B1 (enExample) |
| JP (1) | JP4276840B2 (enExample) |
| KR (1) | KR100910928B1 (enExample) |
| CN (1) | CN1235579C (enExample) |
| AR (1) | AR035756A1 (enExample) |
| AT (1) | ATE361745T1 (enExample) |
| BR (1) | BR0207645A (enExample) |
| CA (1) | CA2439295C (enExample) |
| CY (1) | CY1106753T1 (enExample) |
| CZ (1) | CZ301203B6 (enExample) |
| DE (1) | DE60220043T2 (enExample) |
| DK (1) | DK1383489T3 (enExample) |
| ES (1) | ES2284845T3 (enExample) |
| HU (1) | HUP0303264A3 (enExample) |
| IL (2) | IL157591A0 (enExample) |
| MX (1) | MXPA03007718A (enExample) |
| MY (1) | MY138156A (enExample) |
| NO (1) | NO20033798L (enExample) |
| NZ (1) | NZ527990A (enExample) |
| PL (1) | PL364680A1 (enExample) |
| PT (1) | PT1383489E (enExample) |
| RS (1) | RS51055B (enExample) |
| RU (1) | RU2300373C2 (enExample) |
| TW (1) | TWI312679B (enExample) |
| WO (1) | WO2002067925A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583087C (en) * | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| DK1809273T3 (da) * | 2004-09-16 | 2010-08-02 | Janssen Pharmaceutica Nv | Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese |
| MX2007004491A (es) * | 2004-10-15 | 2007-08-08 | Johnson & Johnson | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| ES2385087T3 (es) * | 2005-07-26 | 2012-07-18 | Sk Biopharmaceuticals Co., Ltd | Procedimientos para tratar trastornos relacionados con sustancias |
| US7632963B2 (en) * | 2006-10-06 | 2009-12-15 | Janssen Pharmaceutica Nv | Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| JP2010508355A (ja) * | 2006-10-30 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 鬱病を処置する方法 |
| EA200970435A1 (ru) * | 2006-10-31 | 2009-10-30 | Янссен Фармацевтика, Н. В. | Лечение общих расстройств развития |
| KR101532823B1 (ko) * | 2010-07-02 | 2015-07-03 | (주)바이오팜솔루션즈 | 페닐 카바메이트 화합물 및 이를 포함하는 근육 이완제 |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US20130060024A1 (en) * | 2011-09-07 | 2013-03-07 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| EP2797878B1 (en) | 2011-12-27 | 2017-08-16 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating stroke |
| CN105189450B (zh) * | 2013-03-12 | 2019-09-13 | 比皮艾思药物研发有限公司 | 氨基甲酸苯酯化合物及包含该化合物的用于预防或治疗精神障碍的组合物 |
| ES2998534T3 (en) * | 2013-03-12 | 2025-02-20 | Bio Pharm Solutions Co Ltd | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy |
| WO2017150903A1 (en) | 2016-02-29 | 2017-09-08 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds, processes for preparing them and their uses |
| KR102635936B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| JP7408643B2 (ja) * | 2018-09-21 | 2024-01-05 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用 |
| EP4204395A4 (en) * | 2020-08-31 | 2024-08-07 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
| EP4211125A4 (en) | 2020-09-10 | 2024-10-02 | Bio-Pharm Solutions Co., Ltd. | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| CN1109880A (zh) * | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| PT1401424E (pt) * | 2001-02-27 | 2007-02-28 | Ortho Mcneil Pharm Inc | Compostos carbamato para utilização na prevenção ou tratamento de distúrbios psicóticos |
| JP2004527492A (ja) * | 2001-02-27 | 2004-09-09 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 運動障害の予防もしくは治療における使用のためのカルバメート化合物 |
| CA2439475C (en) * | 2001-02-27 | 2010-05-18 | Carlos R. Plata-Salaman | Carbamate compounds for use in preventing or treating bipolar disorder |
-
2002
- 2002-02-21 PT PT02714977T patent/PT1383489E/pt unknown
- 2002-02-21 DK DK02714977T patent/DK1383489T3/da active
- 2002-02-21 CN CNB028087178A patent/CN1235579C/zh not_active Expired - Fee Related
- 2002-02-21 BR BR0207645-4A patent/BR0207645A/pt not_active Application Discontinuation
- 2002-02-21 US US10/081,764 patent/US20020165273A1/en not_active Abandoned
- 2002-02-21 MX MXPA03007718A patent/MXPA03007718A/es active IP Right Grant
- 2002-02-21 WO PCT/US2002/005541 patent/WO2002067925A1/en not_active Ceased
- 2002-02-21 JP JP2002567292A patent/JP4276840B2/ja not_active Expired - Fee Related
- 2002-02-21 HU HU0303264A patent/HUP0303264A3/hu unknown
- 2002-02-21 DE DE60220043T patent/DE60220043T2/de not_active Expired - Lifetime
- 2002-02-21 KR KR1020037011302A patent/KR100910928B1/ko not_active Expired - Fee Related
- 2002-02-21 CA CA2439295A patent/CA2439295C/en not_active Expired - Fee Related
- 2002-02-21 RU RU2003128982/14A patent/RU2300373C2/ru not_active IP Right Cessation
- 2002-02-21 PL PL02364680A patent/PL364680A1/xx unknown
- 2002-02-21 ES ES02714977T patent/ES2284845T3/es not_active Expired - Lifetime
- 2002-02-21 NZ NZ527990A patent/NZ527990A/en unknown
- 2002-02-21 IL IL15759102A patent/IL157591A0/xx unknown
- 2002-02-21 EP EP02714977A patent/EP1383489B1/en not_active Expired - Lifetime
- 2002-02-21 RS YUP-674/03A patent/RS51055B/sr unknown
- 2002-02-21 AT AT02714977T patent/ATE361745T1/de active
- 2002-02-21 CZ CZ20032313A patent/CZ301203B6/cs not_active IP Right Cessation
- 2002-02-27 TW TW091103504A patent/TWI312679B/zh active
- 2002-02-27 AR ARP020100697A patent/AR035756A1/es unknown
- 2002-02-27 MY MYPI20020697A patent/MY138156A/en unknown
-
2003
- 2003-08-26 NO NO20033798A patent/NO20033798L/no not_active Application Discontinuation
- 2003-08-26 IL IL157591A patent/IL157591A/en not_active IP Right Cessation
-
2004
- 2004-03-10 US US10/797,795 patent/US20040171679A1/en not_active Abandoned
-
2007
- 2007-07-24 CY CY20071100982T patent/CY1106753T1/el unknown
-
2008
- 2008-09-10 US US12/207,816 patent/US20090005442A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4276840B2 (ja) | 神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 | |
| US20090137652A1 (en) | Methods for neuroprotection | |
| JP4276839B2 (ja) | 双極性障害の予防もしくは治療における使用のためのカルバメート化合物 | |
| TWI250872B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| JP4276838B2 (ja) | 疼痛（ｐａｉｎ）の治療における使用のためのカルバメート化合物 | |
| MXPA03007722A (es) | Compuestos de carbamato para usar en la prevencion o tratamiento de trastornos sicoticos. | |
| AU2002242296A1 (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| MX2007004491A (es) | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. | |
| AU2002247203B2 (en) | Carbamate compounds for use in preventing or treating neurodegenerative disordrers | |
| HK1060516B (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| AU2002247203A1 (en) | Carbamate compounds for use in preventing or treating neurodegenerative disordrers | |
| RU2303445C2 (ru) | Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью | |
| HK1065486B (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| RS50946B (sr) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola u veza sa klasterskim i migrenskim glavoboljama | |
| JP2017509617A (ja) | 抗異痛活性および抗痛覚過敏活性を有する新規化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041130 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090109 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090303 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090309 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |